

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 714 663 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
15.01.1997 Bulletin 1997/03

(51) Int Cl. 6: A61K 45/06, A61K 31/445
// (A61K31/445, 31:135),
(A61K31/445, 31:145),
(A61K31/445, 31:34),
(A61K31/445, 31:40)

(21) Application number: 95308407.6

(22) Date of filing: 25.11.1995

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE

(30) Priority: 28.11.1994 US 345672

(71) Applicant: ELI LILLY AND COMPANY
Indianapolis, Indiana 46285 (US)

(72) Inventors:

• Ogulza, Juan Ignacio
28700 San Sebastian de los Reyes Madrid (ES)

• Wong, David Taiwai
Indianapolis, Indiana 46226 (US)

(74) Representative: Tapping, Kenneth George et al
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)

(54) Potentiation of drug response by a serotonin 1A receptor antagonist

(57) The power of citalopram, fluvoxamine and paroxetine to increase the availability of serotonin, nore-

pinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.

EP 0 714 663 A3